A new study has shown that people taking aspirin to reduce pain have pancreatic cancer much less often than those who use other pain relievers. A similar positive relationship was found between the daily intake of small doses of aspirin for the prevention of heart disease and the risk of cancer.
A study by American scientists shows that the regular intake of acetylsalicylic acid (aspirin) in relation to certain pain is associated with a significant reduction in the probability of a malignant pancreatic tumor.
It is possible that aspirin is useful not only as an anti-inflammatory and painkiller. In a new study, it has been shown that people who take aspirin to relieve pain (for example, major or joint pain) have a much lower risk of developing pancreatic cancer than those with other pain relievers. The same positive relationship was found between the daily intake of small doses of aspirin for the prevention of heart disease and the risk of cancer.
The study was conducted by scientists at the College of Medicine at the Mayo Clinic (Rochester, USA). Scientists compared the effects on the development of pancreatic cancer of the three most common types of analgesics: aspirin, acetaminophen (paracetamol) and other nonsteroidal anti-inflammatory drugs (NSAIDs). 904 patients diagnosed with pancreatic cancer and a little more than 1200 healthy volunteers participated in the work. All of them took these or other painkillers.
After taking into account such risk factors for pancreatic cancer as overweight and smoking, it turned out that taking aspirin at least once a month reduces the probability of cancer by 29%. Other NSAIDs and paracetamol did not make such a positive action.
However, scientists warn that the study of beneficial effects of aspirin just begins, and the drug may not fit all people. Therefore, the question of taking these medications should be taken in conjunction with the doctor because aspirin has a very serious side effects (eg, bleeding ulcers and gastric mucosa), said lead researcher Dr. Ksyan-Lin Tan (Xiang-LinTan).
Scientists presented their results at the 102nd Annual Scientific Conference of the American Association for the Study of Malignant Neoplasms, which took place in Orlando, Florida, USA.